Compare Heron Therapeutics Inc (HRTX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Growth Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Vanguard Growth Index Fund ETF trades at $86.16. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | VUG | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.96 | $90.29 |
52-Week Low | $0.39 | $70.00 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
VUG trades at $85.32, up 0.06% with a bearish technical signal from moving averages. The ETF's low expense ratio of 0.03% and strong historical returns, including a 411% total return over the past decade per The Motley Fool (2026-07-12), highlight its cost efficiency. Recent news emphasizes its growth focus and tech-heavy holdings, with a stock split executed on 21 April 2026. Support levels are clustered around $84-$85, indicating potential near-term stability.
Outlook remains positive for long-term investors due to VUG's low-cost structure and exposure to high-growth U.S. large-cap stocks. Risks include high concentration in technology sectors and market volatility. Analyst sentiment is generally favorable, supporting a buy-and-hold strategy for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
